What is the treatment for Mycoplasma urealyticum infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for Mycoplasma urealyticum infection is doxycycline at a dose of 100 mg twice daily for 7 days, as recommended by the European Association of Urology guidelines 1. This recommendation is based on the most recent and highest quality study available, which suggests that doxycycline is an effective treatment option for Ureaplasma urealyticum infection, and by extension, Mycoplasma urealyticum infection, given their similar characteristics and treatment approaches. Some key points to consider when treating Mycoplasma urealyticum infection include:

  • The use of alternative antibiotics such as azithromycin (1.0–1.5 g p.o. SD) in cases where doxycycline is not suitable 1.
  • The importance of treating sexual partners simultaneously to prevent reinfection 1.
  • The need for follow-up testing to confirm cure in persistent cases 1.
  • The natural resistance of Mycoplasma urealyticum to antibiotics that target cell wall synthesis, such as penicillins and cephalosporins, which is why specific antibiotics that inhibit protein synthesis or DNA replication are required for effective treatment 1. It is essential to note that the treatment approach may vary depending on the specific circumstances of the infection, and healthcare providers should consult the most recent guidelines and studies to ensure the best possible outcomes for their patients 1.

From the Research

Treatment Options for Mycoplasma urealyticum Infection

  • The treatment for Mycoplasma urealyticum infection is not directly addressed in the provided studies, as they primarily focus on Ureaplasma urealyticum and other mycoplasma species.
  • However, some studies suggest that antibiotics such as azithromycin 2, levofloxacin 3, 4, and doxycycline 2, 5, 6 may be effective against mycoplasma infections in general.
  • A study on Ureaplasma urealyticum found that azithromycin has a comparable therapeutic effect to doxycycline and placebo 2.
  • Another study found that levofloxacin showed greater activity against Ureaplasma urealyticum and Mycoplasma hominis compared to other antibiotics tested 3.
  • A study on non-gonococcal urethritis found that levofloxacin 500 mg once daily for 7 days achieved a microbiological eradication rate of 100% for Ureaplasma urealyticum 4.
  • A comparative study of roxithromycin and doxycycline found that doxycycline was successful in eradicating Ureaplasma urealyticum in 87% of cases, while roxithromycin was successful in 73% of cases 6.

Antibiotic Susceptibilities

  • The susceptibility of Mycoplasma urealyticum to various antibiotics is not directly addressed in the provided studies.
  • However, studies on Ureaplasma urealyticum and Mycoplasma hominis suggest that these organisms may be susceptible to antibiotics such as levofloxacin, doxycycline, and erythromycin 3, 5.
  • A study on Ureaplasma urealyticum found that the MIC90 values for levofloxacin, ofloxacin, ciprofloxacin, fleroxacin, doxycycline, and erythromycin were 1 mg/L, 2 mg/L, 4 mg/L, 4 mg/L, 1 mg/L, and 8 mg/L, respectively 3.
  • Another study found that the MIC90 values for doxycycline, chloramphenicol, ciprofloxacin, clindamycin, and gentamicin against Ureaplasma urealyticum were 2 micrograms/ml, 8 micrograms/ml, 8 micrograms/ml, 16 micrograms/ml, and 32 micrograms/ml, respectively 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.